Skip to Main Content
TRC_PLH
Menu
    • Products
      • CriticalPoint
      • Hospital Pharmacist's Letter
      • Hospital Pharmacy Technician's Letter
      • Learning Management Portal
      • NatMed Advisor
      • NatMed Pro
      • NetCE All Access
      • NetCE All Access: Behaviorial Health
      • Pharmacist's Letter
      • Pharmacist's Letter Canada
      • Pharmacy Technician's Letter
      • Pharmacy Technician's Letter Canada
      • Prescriber Insights
      • RxAdvanced
      • RxSelect

    Subscribe Login
  • Home
  • Letter
    • Current Issue
    • Past Issues
    • Suggest a Topic
  • Browse
    • Subject
    • Featured Charts & Graphics
    • Gender-Related Care
    • Diabetes Resources
    • Immunization Resources
    • Natural Medicines Resources
    • All Charts & Graphics
  • Podcasts
  • Charts & Graphics
    • Featured Charts & Graphics
    • Diabetes Drugs
    • Do Not Crush List
    • IV Fluid Safety
    • New Drugs
    • Opioid Dosing
    • Vancomycin Dosing
    • All Charts & Graphics >
  • CE/CME & Training
    • CE Organizer
    • Available Courses
    • My Completions
    • Live Webinars
  • Help
    • User Support
    • Contact Us

Upgrade Your Browser

We no longer support this version of your browser. We recommend that you upgrade to the latest version of Internet Explorer, Firefox, Chrome or Safari to improve your security and experience using this website.

Return to the course you were viewing

NatMed Pro, the largest natural medicines database, just got a major upgrade! With faster performance, a redesigned interface, and improved navigation, it's easier than ever to find the evidence-based answer you need. Explore Now
Become a smarter pharmacist in minutes! More CE, more resources, more value. Choose your Hospital Pharmacist's Letter membership and elevate your pharmacy practice today. Subscribe Now
  1. Home
  2. Browse
  3. Cardiology
  4. Antithrombotics
  5. Treatment

Treatment

  • Angina (18)
  • Antithrombotics (289)
    • Drug-Induced Thrombosis (28)
    • Prevention (44)
    • Reversal (22)
    • Treatment (264)
      • Apixaban (Eliquis) (100)
      • Aspirin (136)
      • Cangrelor (Kengreal) (4)
      • Clopidogrel (Plavix) (80)
      • Dabigatran (Pradaxa) (101)
      • Edoxaban (Savaysa) (41)
      • Low Molecular Weight Heparins (63)
      • Other (40)
      • Prasugrel (Effient) (42)
      • Rivaroxaban (Xarelto) (110)
      • Ticagrelor (Brilinta) (40)
      • Vorapaxar (Zontivity) (1)
      • Warfarin - Drug Interactions (29)
      • Warfarin - Treatment (120)
  • Arrhythmias (131)
  • Blood Pressure (33)
  • Cardiovascular Disease and Depression (6)
  • Cholesterol (23)
  • CPR (6)
  • Dyslipidemia (168)
  • Endocarditis (21)
  • Heart Disease (84)
  • Heart Failure (155)
  • Hypertension (225)
  • Hypotension (27)
  • Ischemic Heart Disease/Acute Coronary Syndromes (244)
  • Myocardial Infarction (48)
  • Peripheral Vascular Disease (8)
  • Pulmonary Arterial Hypertension (1)
  • Raynaud's (2)
  • Resources (699)
  • Stroke (119)
241 - 255 of 264 Results
Sort Results:
  • Title: Ascending (A-Z)
  • Date: Newest First
  • Date: Oldest First
PL Voices: Aspirin for Prevention of Thrombosis March 2012
PL Voices: Warfarin vs Pradaxa or Xarelto for Atrial Fib December 2011
PL Voices: Oral Anticoagulants October 2011
Commentary: Discontinuing Antiplatelet Agents September 2011
PL Voices: Discontinuing Antiplatelet Agents September 2011
Commentary: New Drug: Brilinta (Ticagrelor) August 2011
Commentary: New Drug: Xarelto (Rivaroxaban) August 2011
Commentary: Off-Label Use of Dabigatran June 2011
Commentary: Extended Storage Time for Pradaxa (Dabigatran) May 2011
Commentary: Duration of Anticoagulation After Venous Thromboembolism April 2011
Guideline: Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension (March 2011) April 2011
Guideline: Antithrombotic Therapy for Venous Thromboembolic Disease (June 2008) April 2011
Commentary: Helping Patients Store and Use Dabigatran Appropriately March 2011
Commentary: New Drug: Pradaxa (Dabigatran) January 2011
Commentary: Approval of Generic Enoxaparin (Lovenox) September 2010
  • « Prev
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • Next »
  • About Us
  • Our Mission
  • Our Team
  • Careers
  • Newsroom
  • Products
  • Pharmacist Solutions
  • Prescriber Solutions
  • Hospital Solutions
  • Retail Solutions
  • Group Practice Solutions
  • Support & Policies
  • Contact Us
  • Access Agreement
  • Privacy Policy

The contents of this website are not intended to be a substitute for professional medical advice, diagnosis, or treatment. See additional information.



© Therapeutic Research Center. All Rights Reserved